Dominic D'Agostino

and then aggressively target pharmacologically circulating glucose and glycolytic enzymes.

And then you have to aggressively target glutamineolysis, circulating glutamine, and also drugs that inhibit glutamine metabolism in

cancer cells.

So you could target glutaminase.

So there's a drug, DON, that Dr. Seyfried uses, and I have not used it.

I've talked to some patients that use it.

It does cause some GI stress.

That's a pretty big heavy hitter.

But you have a number of different things, sodium phenylbutyrate, glycerol phenylbutyrate, which is actually an HDAC inhibitor.

It will bind up glutamine, and then you pee some of it out.

There's EGCG.

There's curcumin.

Quercetin has glutamine, glutaminase-inhibiting properties.

So there's cell data, there's animal data.

I understand your frustration.

Yeah, I'm super frustrated.

That's what motivates me.

I would encourage people to read that framework of the ketone.

And then it's really important to access the supplementary information, which gives all the different drugs and everything.

So we have to ask the question, who's going to fund this clinical trial?